What is Cyfra 21-1 quantification?

This is an automatically translated article.

To screen, diagnose and treat all types of cancer, especially lung cancer, the quantitative test Cyfra 21-1 is necessary. In addition to the quantitative test of Cyfra 21-1, the patient needs ultrasound, X-ray, CT scan... to determine the specific condition and level of the disease.

1. What is Cyfra 21-1 quantification?

Quantification of Cyfra 21 - 1 is a cancer marker commonly found in blood. This quantification is used as an aid in the diagnosis and monitoring of lung cancer and other cancers of the esophagus, breast, pancreas, cervix or bladder.
Cyfra 21 - 1 can be increased in lung cancer, especially in non-small cell lung cancer, it can also be increased in some other cancers such as esophageal, breast, pancreatic, cervical cancer, bladder.
Cyfra 21 - 1 usually decreases after surgery or chemotherapy for non-small cell lung cancer, and may increase again when the cancer recurs.

2. Role of Cyfra 21–1 . quantification

The Cyfra 21-1 test is used to diagnose lung cancer and benign lung diseases, as well as between non-small cell lung cancer and small cell lung cancer, and between primary and secondary lung cancer Cyfra 21- 1 used to predict disease Cyfra 21-1 is used to monitor disease progression. However, the quantification of Cyfra 21-1 in blood has no absolute value in diagnosing lung cancer and other diseases. Many people have cancer, but this index does not increase. Therefore, in addition to the Cyfra 21-1 test, the patient needs ultrasound, X-ray, CT scan ... to determine the specific status and extent of the disease.

3. How much Cyfra 21 - 1 is dangerous?

Through blood tests, a normal serum level of Cyfra 21-1 is < 3.3 μg/ml.
Histopathological studies show that Cyfra 21-1 is elevated in lung cancer. A slight increase (>3.3 μg/ml) of this index is seen in some benign diseases such as liver disease and renal failure, some other extrapulmonary malignancies such as adnexa, gastrointestinal gland, mesothelioma. pleura, urinary tract.
However, Cyfra 21-1 concentrations were highest in lung cancer, mainly non-small cell lung cancer. When compared with other cancer markers, Cyfra 21-1 was the most sensitive oncogene in lung cancer, with the highest concentration in epidermal lung cancer. The sensitivity of Cyfra 21-1 ranges from 30-75% in non-small cell lung cancer and from 20-60% in small cell lung cancer. Cyfra 21-1 is very valuable in diagnosis, prognosis (mainly non-small cell lung cancer), early diagnosis of recurrence and monitoring of treatment.
Specifically:
Healthy people have Cyfra 21 - 1 level < 3.3 μg/ml People with benign lung diseases have serum Cyfra 21-1 levels < 3.3 μg/mL People with lung cancer have a level of Cyfra 21 - 1 < 3.5 μg/mL Cyfra 21 - 1 usually decreases after surgery or chemotherapy and may increase again when the cancer recurs.

4. Clinical significance of the Cyfra 21 - 1 . test

4.1 In malignant lung cancers If the blood test shows a positive (+) Cyfra 21 - 1 count, it may be related to the solid tumor type.
Lung cancer: In the diagnosis of primary lung cancer in general, Cyfra 21 - 1 with a cutoff value of 3.5 ng/mL has a sensitivity of 43% and a specificity of 89%. Non-small cell lung cancer: Cyfra 21-1 has a sensitivity of 59% to 78% and a specificity of 94%. Small cell lung cancer: Cyfra 21-1 sensitivity is 19% and specificity is 94%. The first selected small cell lung cancer marker was NSE with a sensitivity of 54%, however, when combined with Cyfra 21-1, the clinical sensitivity of NSE increased to 62%. Squamous cell lung cancer: Cyfra 21 - 1 has a positive diagnostic value (+) of 84.6%, while SCC and CEA only have a positive diagnostic value (+) of 30 and 20%, respectively. . Lung adenocarcinoma and large cell lung cancer: Cyfra 21 - 1 is a marker of adenocarcinoma with a sensitivity of 74.3% and of large cell lung cancer with a sensitivity of 75, 3%. The sensitivity of this cancer marker is increased by about 10% when combined with CEA. If both of these cancer markers are positive (+), then to track the progression of these cancers over time, just one cancer marker is enough. 4.2 In benign diseases Benign lung diseases: In chronic obstructive pulmonary diseases, pneumonia, pulmonary tuberculosis, chronic bronchitis, bronchial asthma, pneumothorax and benign lung tumors, the level of Cyfra 21 – 1 serum is usually < 3.3 μg/L. Benign pelvic disease: In endometritis, ovarian cysts, adnexitis, benign ovarian tumors, urinary tract infections, renal cysts, benign bladder tumors, Cyfra level 21-1 Serum is usually < 3.1 μg/L. Benign gastrointestinal diseases: In acute and chronic hepatitis, pancreatitis, cholangitis, gastritis, ileitis, colitis, colon polyps, the serum level of Cyfra 21-1 is usually < 3.0 μg/L. Renal failure : Serum Cyfra 21-1 level < 3.0 μg/L and rarely exceeds this level. 4.3 In other cancers Esophageal cancer: Cyfra 21 – 1 at a cut-off value of 1.40 ng/mL had a sensitivity of 36% for esophageal cancer (45.5% for carcinoma). squamous cell, 17.6% for adenocarcinoma) with a specificity of 97.3%. Recurrence after esophageal surgery represented by the return of Cyfra 21-1 can occur 3, 4 months after surgery. Breast cancer: Cyfra 21-1 increased rates were 83.3% in stage IV and 84.6% in recurrent disease, while these rates for CA 15-3 were 83.3% and 34, respectively. .6% and of CEA respectively 41.7% and 26.9%. Pancreatic cancer: Cyfra 21-1 is valuable in the diagnosis of pancreatic cancer. Cyfra 21-1 when combined with CA 19-9 can be useful in the diagnosis of pancreatic cancer, with an accuracy of 86.3% and 81.5%, respectively. Cervical cancer: The plasma level of Cyfra 21-1 was significantly higher in patients with cervical cancer and endometrial cancer than in those with benign uterine tumors (P<0). .05). Bladder cancer: The sensitivity and specificity of serum Cyfra 21-1 were 42% and 94%, respectively, and the sensitivity and specificity of urinary Cyfra 21-1 were 82% and 80%, respectively. The accuracy of Cyfra 21-1 in serum and urine was 88% and 87%, respectively.

Vinmec Ha Long International General Hospital is one of the trusted addresses chosen by many customers to perform the Cyfra 21-1 quantitative test. Quantitative testing technique Cyfra 21-1 at Vinmec Ha Long using Cobas E automatic immunoassay machine gives the most accurate results and successfully supports the treatment of lung cancer as well as other cancers for humans. sick.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.